Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal
NCT03585348 is an observational study sponsored by Beth Israel Deaconess Medical Center. As of 18 Nov 2026, it is completed. It studies Neuromuscular Blockade, Residual Curarisation, Postoperative and 1 more condition. The registry lists an enrollment of 265,537 participants at 2 sites in 1 country. The registry lists a start date of 29 Jun 2018 and a primary completion date of 31 Mar 2021.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03585348 |
| Status | Completed |
| Study type | Observational study |
| Lead sponsor | Beth Israel Deaconess Medical Center |
| Enrollment | 265,537 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Neuromuscular Blockade, Residual Curarisation, Postoperative and Surgery Under General Anaesthesia |
| Start | 29 Jun 2018 |
| Primary completion | 31 Mar 2021 |
| Study completion | 31 Mar 2021 |
| Last update posted | 25 Aug 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Philipp Fassbender, MD
Beth Israel Deaconess Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beth Israel Deaconess Medical Center
Boston
- Massachusetts General Hospital
Boston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT03585348
Each answer restates registry values shown on this page.
What is NCT03585348?
NCT03585348 is an observational study sponsored by Beth Israel Deaconess Medical Center. It studies Neuromuscular Blockade, Residual Curarisation, Postoperative and 1 more condition.
Who leads NCT03585348?
The registry names Philipp Fassbender, MD (principal investigator, Beth Israel Deaconess Medical Center) as the overall official.
Where does NCT03585348 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
When did NCT03585348 end?
The registry lists a primary completion date of 31 Mar 2021 and a study completion date of 31 Mar 2021. The sponsor last updated the record on 25 Aug 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.